Autonomix Medical (Nasdaq:AMIX) announced today that it advanced its proprietary sensing catheter through a final design ...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, ...

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption ("IDE"), and if ap ...

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Study Overview: Celgene Corporation is conducting a clinical ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

GCP compliance spans multiple parties; the article reviews their duties and proposes joint governance. By丨 Yongbin GE, ...

To navigate the post-LDC era successfully, Bangladesh must transition from a volume-driven, generics-dominated model to one ...

The analysis highlighted a shift in heart failure diagnoses, with hypertensive heart disease with and without chronic kidney disease as prevalent diagnoses, underlining coding variability and ...

Solna, Sweden, August 14, 2025 - Vivesto AB, an oncology-focused development company, today announced that the first patient has been dosed in the company's Paccal Vet dose-finding study in cats with ...

The largest study of its kind has revealed that medication for attention-deficit/hyperactivity disorder (ADHD) has a ...